Dr Jasset Smith, PSYD, LMHC | |
1881 N University Dr, Suite 104, Coral Springs, FL 33071-8915 | |
(954) 340-0888 | |
(954) 346-0909 |
Full Name | Dr Jasset Smith |
---|---|
Gender | Female |
Speciality | Psychologist |
Location | 1881 N University Dr, Coral Springs, Florida |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1033651286 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YM0800X | Counselor - Mental Health | MH10274 (Florida) | Secondary |
103T00000X | Psychologist | PY9755 (Florida) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Jasset Smith, PSYD, LMHC 1881 N University Dr, Suite 104, Coral Springs, FL 33071-8915 Ph: (954) 340-0888 | Dr Jasset Smith, PSYD, LMHC 1881 N University Dr, Suite 104, Coral Springs, FL 33071-8915 Ph: (954) 340-0888 |
News Archive
CareFirst BlueCross BlueShield, the largest private insurer in the Washington [DC] region, plans to announce Tuesday that it will give $8.5 million to a dozen safety-net clinics to help them use a coordinated primary-care approach to treat their most vulnerable patients, executives said. ... One of the recipients is the Arlington Free Clinic, which provides free health care to about 1,600 low-income, uninsured residents.
The new drugs in development by pharmaceutical makers are injectable medications that block a protein called PCSK9. These drugs have shown promise in early clinical trials for slashing bad LDL cholesterol further than widely used statins can alone. Their biggest advocates say PCSK9 blockers have the potential to be the next multibillion-dollar class of heart drugs.
St Petersburg University researchers, led by Professor Raul R. Gainetdinov, Director of the Institute of Translational Biomedicine and Academic Supervisor of the St Petersburg University Hospital, have found a new role for recently discovered neurotransmitter system that uses the trace amine-associated receptor 5 (TAAR5) for neurotransmission.
Genentech, Inc., a wholly owned member of the Roche Group, announced today the topline results of a Phase III trial led by the U.S. Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute investigating the use of AvastinĀ® (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC).
Associate Professor Menglin Chen has received a major grant from the Carlsberg Foundation to develop a completely new method of regenerating brain and heart cells.
› Verified 9 days ago